Amylyx Pharmaceuticals Financials
Amylyx Pharmaceuticals (AMLX) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash balances are being rebuilt through equity financing while operating losses remain anchored in R&D and overhead, not leverage.
Cash rose from$77.4M in FY2024 to$226.7M in FY2025, which makes liquidity look materially better than a year earlier. But operating cash burn was still-$123.3M , and financing inflows of$257.0M supplied the difference, so the stronger cash position came from external capital rather than the business funding itself.
FY2023's profitability was not yet a stable base: net income of
This is not a debt-funded balance sheet: FY2025 liabilities were only
Financial Health Signals
Amylyx Pharmaceuticals does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Amylyx Pharmaceuticals scores 90.63, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.3B) relative to total liabilities ($27.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Amylyx Pharmaceuticals passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Amylyx Pharmaceuticals reported a net loss of $144.7M while operations used $123.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Amylyx Pharmaceuticals generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Amylyx Pharmaceuticals's EBITDA was -$152.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 51.3% from the prior year.
Amylyx Pharmaceuticals reported -$144.7M in net income in fiscal year 2025. This represents an increase of 52.0% from the prior year.
Amylyx Pharmaceuticals earned -$1.53 per diluted share (EPS) in fiscal year 2025. This represents an increase of 65.5% from the prior year.
Cash & Balance Sheet
Amylyx Pharmaceuticals recorded an outflow of $123.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 26.4% from the prior year.
Amylyx Pharmaceuticals held $226.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Amylyx Pharmaceuticals's ROE was -47.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 135.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Amylyx Pharmaceuticals invested $90.4M in research and development in fiscal year 2025. This represents a decrease of 13.1% from the prior year.
Amylyx Pharmaceuticals invested $138K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 12.1% from the prior year.
Not reported for fiscal year 2025.
AMLX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Revenue | N/A | $0-100.0% | $87.4M-77.1% | $380.8M+1612.9% | $22.2M+7700.0% | $285K |
| Cost of Revenue | N/A | $0-100.0% | $6.0M-76.6% | $25.4M+750.0% | $3.0M | N/A |
| Gross Profit | N/A | $0-100.0% | $81.4M-77.1% | $355.3M+1747.2% | $19.2M | N/A |
| R&D Expenses | N/A | $90.4M-13.1% | $104.1M-18.8% | $128.2M+37.2% | $93.5M+112.2% | $44.0M |
| SG&A Expenses | N/A | $62.9M-45.0% | $114.3M-39.3% | $188.4M+48.2% | $127.1M+226.5% | $38.9M |
| Operating Income | N/A | -$153.3M+51.3% | -$314.7M-911.1% | $38.8M+119.3% | -$201.3M-143.5% | -$82.7M |
| Income Tax | N/A | $46K+111.7% | -$393K-107.8% | $5.0M+549.4% | $774K | N/A |
| Net Income | N/A | -$144.7M+52.0% | -$301.7M-712.4% | $49.3M+124.8% | -$198.4M-125.6% | -$87.9M |
| EPS (Diluted) | — | -$1.53+65.5% | -$4.43-732.9% | $0.70+120.6% | -$3.39 | -$13.35 |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AMLX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Total Assets | $332.6M+71.8% | $193.6M-62.6% | $517.5M+32.2% | $391.5M+270.6% | $105.6M |
| Current Assets | $323.7M+70.9% | $189.4M-59.2% | $464.7M+21.6% | $382.1M+264.1% | $105.0M |
| Cash & Equivalents | $226.7M+192.9% | $77.4M-54.5% | $170.2M+172.2% | $62.5M+24.6% | $50.2M |
| Inventory | N/A | $0-100.0% | $38.3M+292.3% | $9.8M | N/A |
| Accounts Receivable | $88K-80.3% | $447K-98.9% | $40.0M+161.7% | $15.3M | N/A |
| Total Liabilities | $27.4M-5.1% | $28.9M-65.6% | $84.0M+65.2% | $50.8M-80.2% | $256.8M |
| Current Liabilities | $22.7M-20.1% | $28.4M-65.4% | $82.0M+76.0% | $46.6M+167.9% | $17.4M |
| Total Equity | $305.3M+85.3% | $164.8M-62.0% | $433.4M+27.3% | $340.6M+325.3% | -$151.2M |
| Retained Earnings | -$751.4M-23.9% | -$606.7M-98.9% | -$304.9M+13.9% | -$354.2M-127.3% | -$155.8M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
AMLX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$126.6M | -$123.3M+26.4% | -$167.6M-1506.6% | $11.9M+106.6% | -$179.9M-140.5% | -$74.8M |
| Capital Expenditures | N/A | $138K-12.1% | $157K-87.3% | $1.2M-50.9% | $2.5M+615.6% | $353K |
| Free Cash Flow | N/A | -$123.5M+26.4% | -$167.8M-1671.5% | $10.7M+105.9% | -$182.4M-142.7% | -$75.2M |
| Investing Cash Flow | -$78.8M | $14.0M-81.4% | $75.7M-17.8% | $92.1M+138.5% | -$239.0M-415.0% | -$46.4M |
| Financing Cash Flow | $196.1M | $257.0M+73758.9% | $348K-90.2% | $3.5M-99.2% | $431.8M+172.4% | $158.5M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AMLX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Gross Margin | N/A | 93.2%-0.1pp | 93.3%+6.8pp | 86.5% | N/A |
| Operating Margin | N/A | -360.2% | 10.2% | -905.7% | -29013.3% |
| Net Margin | N/A | -345.4% | 12.9% | -892.4% | -30853.0% |
| Return on Equity | -47.4%+135.7pp | -183.1%-194.5pp | 11.4%+69.6pp | -58.2% | N/A |
| Return on Assets | -43.5%+112.3pp | -155.8%-165.3pp | 9.5%+60.2pp | -50.7%+32.6pp | -83.3% |
| Current Ratio | 14.27+7.6x | 6.67+1.0x | 5.66-2.5x | 8.20+2.2x | 6.03 |
| Debt-to-Equity | 0.09-0.1x | 0.180.0x | 0.190.0x | 0.15 | N/A |
| FCF Margin | N/A | -192.1% | 2.8% | -820.5% | -26369.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Amylyx Pharmaceuticals Ranks
Frequently Asked Questions
What is Amylyx Pharmaceuticals's annual revenue?
Amylyx Pharmaceuticals (AMLX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Amylyx Pharmaceuticals's revenue growing?
Amylyx Pharmaceuticals (AMLX) revenue declined by 100.0% year-over-year, from $87.4M to $0 in fiscal year 2025.
Is Amylyx Pharmaceuticals profitable?
No, Amylyx Pharmaceuticals (AMLX) reported a net income of -$144.7M in fiscal year 2025.
What is Amylyx Pharmaceuticals's EBITDA?
Amylyx Pharmaceuticals (AMLX) had EBITDA of -$152.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Amylyx Pharmaceuticals's return on equity (ROE)?
Amylyx Pharmaceuticals (AMLX) has a return on equity of -47.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Amylyx Pharmaceuticals's free cash flow?
Amylyx Pharmaceuticals (AMLX) recorded an outflow of $123.5M in free cash flow during fiscal year 2025. This represents a 26.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Amylyx Pharmaceuticals's operating cash flow?
Amylyx Pharmaceuticals (AMLX) recorded an outflow of $123.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Amylyx Pharmaceuticals's total assets?
Amylyx Pharmaceuticals (AMLX) had $332.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Amylyx Pharmaceuticals's capital expenditures?
Amylyx Pharmaceuticals (AMLX) invested $138K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Amylyx Pharmaceuticals spend on research and development?
Amylyx Pharmaceuticals (AMLX) invested $90.4M in research and development during fiscal year 2025.
What is Amylyx Pharmaceuticals's current ratio?
Amylyx Pharmaceuticals (AMLX) had a current ratio of 14.27 as of fiscal year 2025, which is generally considered healthy.
What is Amylyx Pharmaceuticals's debt-to-equity ratio?
Amylyx Pharmaceuticals (AMLX) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Amylyx Pharmaceuticals's return on assets (ROA)?
Amylyx Pharmaceuticals (AMLX) had a return on assets of -43.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Amylyx Pharmaceuticals's cash runway?
Based on fiscal year 2025 data, Amylyx Pharmaceuticals (AMLX) had $226.7M in cash against an annual operating cash burn of $123.3M. This gives an estimated cash runway of approximately 22 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Amylyx Pharmaceuticals's Altman Z-Score?
Amylyx Pharmaceuticals (AMLX) has an Altman Z-Score of 90.63, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Amylyx Pharmaceuticals's Piotroski F-Score?
Amylyx Pharmaceuticals (AMLX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Amylyx Pharmaceuticals's earnings high quality?
Amylyx Pharmaceuticals (AMLX) reported a net loss of $144.7M while operations used $123.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.